Reported Earnings • May 28
Full year 2026 earnings released: EPS: ₹17.29 (vs ₹16.39 in FY 2025) Full year 2026 results: EPS: ₹17.29 (up from ₹16.39 in FY 2025). Revenue: ₹22.8b (up 8.4% from FY 2025). Net income: ₹2.81b (up 5.5% from FY 2025). Profit margin: 12% (in line with FY 2025). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 13% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • May 27
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹430, the stock trades at a trailing P/E ratio of 32.1x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 47% over the past three years. Reported Earnings • Feb 07
Third quarter 2026 earnings released: EPS: ₹1.74 (vs ₹2.28 in 3Q 2025) Third quarter 2026 results: EPS: ₹1.74 (down from ₹2.28 in 3Q 2025). Revenue: ₹4.86b (up 4.6% from 3Q 2025). Net income: ₹283.0m (down 24% from 3Q 2025). Profit margin: 5.8% (down from 8.0% in 3Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 12% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Nov 06
Second quarter 2026 earnings released Second quarter 2026 results: Revenue: ₹4.94b (down 3.9% from 2Q 2025). Net income: ₹283.7m (down 61% from 2Q 2025). Profit margin: 5.7% (down from 14% in 2Q 2025). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Duyuru • Aug 26
FDC Limited, Annual General Meeting, Sep 25, 2025 FDC Limited, Annual General Meeting, Sep 25, 2025, at 10:00 Indian Standard Time. Reported Earnings • Aug 08
First quarter 2026 earnings released: EPS: ₹7.45 (vs ₹7.31 in 1Q 2025) First quarter 2026 results: EPS: ₹7.45 (up from ₹7.31 in 1Q 2025). Revenue: ₹6.84b (up 7.2% from 1Q 2025). Net income: ₹1.21b (up 1.9% from 1Q 2025). Profit margin: 18% (in line with 1Q 2025). Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 21% per year. Duyuru • Aug 02
FDC Limited to Report Q1, 2026 Results on Aug 07, 2025 FDC Limited announced that they will report Q1, 2026 results on Aug 07, 2025 Reported Earnings • May 29
Full year 2025 earnings released: EPS: ₹16.39 (vs ₹18.59 in FY 2024) Full year 2025 results: EPS: ₹16.39 (down from ₹18.59 in FY 2024). Revenue: ₹22.0b (up 13% from FY 2024). Net income: ₹2.67b (down 13% from FY 2024). Profit margin: 12% (down from 16% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 19% per year whereas the company’s share price has increased by 21% per year. Duyuru • May 22
FDC Limited to Report Q4, 2025 Results on May 28, 2025 FDC Limited announced that they will report Q4, 2025 results on May 28, 2025 Reported Earnings • Feb 14
Third quarter 2025 earnings released: EPS: ₹2.28 (vs ₹4.86 in 3Q 2024) Third quarter 2025 results: EPS: ₹2.28 (down from ₹4.86 in 3Q 2024). Revenue: ₹4.64b (up 1.3% from 3Q 2024). Net income: ₹370.4m (down 53% from 3Q 2024). Profit margin: 8.0% (down from 17% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Buy Or Sell Opportunity • Feb 10
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 7.6% to ₹461. The fair value is estimated to be ₹586, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 14%. Duyuru • Feb 07
FDC Limited to Report Q3, 2025 Results on Feb 12, 2025 FDC Limited announced that they will report Q3, 2025 results on Feb 12, 2025 Buy Or Sell Opportunity • Jan 22
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 9.9% to ₹466. The fair value is estimated to be ₹586, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 14%. Duyuru • Dec 19
FDC Limited Receives Final Approval from US FDA for the Company's Abbreviated New Drug Application for Cefixime 400 mg Tablets FDC Limited announced that the Company has received final approval from US FDA for the Company's Abbreviated New Drug Application (ANDA) for Cefixime 400 mg Tablets. Upcoming Dividend • Nov 15
Upcoming dividend of ₹5.00 per share Eligible shareholders must have bought the stock before 22 November 2024. Payment date: 06 December 2024. Payout ratio is a comfortable 26% and this is well supported by cash flows. Trailing yield: 2.0%. Within top quartile of Indian dividend payers (1.2%). Higher than average of industry peers (0.7%). Reported Earnings • Nov 07
Second quarter 2025 earnings released: EPS: ₹4.43 (vs ₹4.22 in 2Q 2024) Second quarter 2025 results: EPS: ₹4.43 (up from ₹4.22 in 2Q 2024). Revenue: ₹5.49b (up 13% from 2Q 2024). Net income: ₹720.4m (up 3.2% from 2Q 2024). Profit margin: 13% (down from 14% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 18% per year. Duyuru • Oct 29
FDC Limited to Report Q2, 2025 Results on Nov 06, 2024 FDC Limited announced that they will report Q2, 2025 results on Nov 06, 2024 Duyuru • Sep 06
FDC Limited Announces Cessation of CA Swati Sandesh Mayekar as Non-Independent Director FDC Limited announced that CA. Swati Sandesh Mayekar Non-Executive Independent Director of the Company have completed her tenure viz. second term of five (5) consecutive years on September 05, 2024 Consequently, she ceases to be the Independent Director of the company, accordingly she also ceases to be the member of various Board committees with effect from 06 September 2024. Duyuru • Aug 28
FDC Limited, Annual General Meeting, Sep 26, 2024 FDC Limited, Annual General Meeting, Sep 26, 2024, at 10:00 Indian Standard Time. Reported Earnings • Aug 08
First quarter 2025 earnings released: EPS: ₹7.31 (vs ₹6.62 in 1Q 2024) First quarter 2025 results: EPS: ₹7.31 (up from ₹6.62 in 1Q 2024). Revenue: ₹6.67b (up 24% from 1Q 2024). Net income: ₹1.19b (up 8.3% from 1Q 2024). Profit margin: 18% (down from 21% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 11% per year. Duyuru • Jul 26
FDC Limited to Report Q1, 2025 Results on Aug 07, 2024 FDC Limited announced that they will report Q1, 2025 results on Aug 07, 2024 Reported Earnings • May 30
Full year 2024 earnings released: EPS: ₹18.58 (vs ₹11.67 in FY 2023) Full year 2024 results: EPS: ₹18.58 (up from ₹11.67 in FY 2023). Revenue: ₹20.4b (up 15% from FY 2023). Net income: ₹3.05b (up 57% from FY 2023). Profit margin: 15% (up from 11% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings. Duyuru • May 03
FDC Limited Announces Board Completion of Tenure of Independent Directors FDC Limited announced that took note of the Completion of tenure of Independent Directors of the Company, namely, Ms. Usha Athreya Chandrasekhar and Mr. Melarkode Ganesan Parameswaran on May 9, 2024. Reported Earnings • Feb 08
Third quarter 2024 earnings released: EPS: ₹4.86 (vs ₹2.45 in 3Q 2023) Third quarter 2024 results: EPS: ₹4.86 (up from ₹2.45 in 3Q 2023). Revenue: ₹4.83b (up 18% from 3Q 2023). Net income: ₹792.3m (up 95% from 3Q 2023). Profit margin: 16% (up from 10.0% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings. Reported Earnings • Nov 09
Second quarter 2024 earnings released: EPS: ₹4.22 (vs ₹3.10 in 2Q 2023) Second quarter 2024 results: EPS: ₹4.22 (up from ₹3.10 in 2Q 2023). Revenue: ₹5.14b (up 15% from 2Q 2023). Net income: ₹698.2m (up 35% from 2Q 2023). Profit margin: 14% (up from 12% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Duyuru • Aug 31
FDC Limited, Annual General Meeting, Sep 27, 2023 FDC Limited, Annual General Meeting, Sep 27, 2023, at 10:00 Indian Standard Time. New Risk • Aug 10
New major risk - Revenue and earnings growth Earnings have declined by 1.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company. Reported Earnings • Aug 10
First quarter 2024 earnings released: EPS: ₹6.62 (vs ₹4.23 in 1Q 2023) First quarter 2024 results: EPS: ₹6.62 (up from ₹4.23 in 1Q 2023). Revenue: ₹5.66b (up 14% from 1Q 2023). Net income: ₹1.10b (up 55% from 1Q 2023). Profit margin: 19% (up from 14% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. Duyuru • Aug 03
FDC Limited to Report Q1, 2024 Results on Aug 09, 2023 FDC Limited announced that they will report Q1, 2024 results on Aug 09, 2023 Reported Earnings • May 30
Full year 2023 earnings released: EPS: ₹11.66 (vs ₹12.82 in FY 2022) Full year 2023 results: EPS: ₹11.66 (down from ₹12.82 in FY 2022). Revenue: ₹18.3b (up 20% from FY 2022). Net income: ₹1.94b (down 10% from FY 2022). Profit margin: 11% (down from 14% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Reported Earnings • Feb 10
Third quarter 2023 earnings released: EPS: ₹2.45 (vs ₹2.11 in 3Q 2022) Third quarter 2023 results: EPS: ₹2.45 (up from ₹2.11 in 3Q 2022). Revenue: ₹4.28b (up 25% from 3Q 2022). Net income: ₹407.5m (up 14% from 3Q 2022). Profit margin: 9.5% (in line with 3Q 2022). Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Duyuru • Feb 01
FDC Limited to Report Q3, 2023 Results on Feb 09, 2023 FDC Limited announced that they will report Q3, 2023 results on Feb 09, 2023 Reported Earnings • Nov 18
Second quarter 2023 earnings released: EPS: ₹3.10 (vs ₹4.28 in 2Q 2022) Second quarter 2023 results: EPS: ₹3.10 (down from ₹4.28 in 2Q 2022). Revenue: ₹4.45b (up 12% from 2Q 2022). Net income: ₹518.4m (down 28% from 2Q 2022). Profit margin: 12% (down from 18% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings. Price Target Changed • Nov 16
Price target increased to ₹375 Up from ₹350, the current price target is provided by 1 analyst. New target price is 32% above last closing price of ₹285. Stock is down 3.3% over the past year. The company is forecast to post earnings per share of ₹20.60 for next year compared to ₹12.82 last year. Duyuru • Aug 30
FDC Limited to Report Q4, 2023 Results on May 23, 2023 FDC Limited announced that they will report Q4, 2023 results on May 23, 2023 Reported Earnings • Aug 05
First quarter 2023 earnings released: EPS: ₹4.23 (vs ₹5.80 in 1Q 2022) First quarter 2023 results: EPS: ₹4.23 (down from ₹5.80 in 1Q 2022). Revenue: ₹5.14b (up 15% from 1Q 2022). Net income: ₹707.4m (down 28% from 1Q 2022). Profit margin: 14% (down from 22% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth. Recent Insider Transactions • Jun 11
Board Member recently bought ₹912k worth of stock On the 8th of June, Melarkode Parameswaran bought around 4k shares on-market at roughly ₹247 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Board Change • Jun 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 3 highly experienced directors. Additional Non-Executive & Independent Director Ambi Parameswaran was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • May 27
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: EPS: ₹12.81 (down from ₹17.73 in FY 2021). Net income: ₹2.16b (down 28% from FY 2021). Revenue missed analyst estimates by 3.1%. Earnings per share (EPS) also missed analyst estimates by 27%. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Price Target Changed • Apr 27
Price target decreased to ₹415 Down from ₹460, the current price target is provided by 1 analyst. New target price is 52% above last closing price of ₹273. Stock is down 12% over the past year. The company is forecast to post earnings per share of ₹17.60 for next year compared to ₹17.73 last year. Reported Earnings • Feb 10
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Third quarter 2022 results: EPS: ₹2.11 (down from ₹4.45 in 3Q 2021). Revenue: ₹3.55b (up 4.2% from 3Q 2021). Net income: ₹356.9m (down 53% from 3Q 2021). Profit margin: 10% (down from 22% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 9.5%. Earnings per share (EPS) also missed analyst estimates by 7.7%. Over the next year, revenue is forecast to grow 22%, compared to a 13% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 20% per year whereas the company’s share price has increased by 24% per year. Reported Earnings • Nov 16
Second quarter 2022 earnings released: EPS ₹4.28 (vs ₹5.15 in 2Q 2021) The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2022 results: Revenue: ₹3.98b (up 7.1% from 2Q 2021). Net income: ₹724.0m (down 18% from 2Q 2021). Profit margin: 18% (down from 24% in 2Q 2021). The decrease in margin was driven by higher expenses. Price Target Changed • Nov 16
Price target decreased to ₹415 Down from ₹470, the current price target is provided by 1 analyst. New target price is 40% above last closing price of ₹297. Stock is down 8.7% over the past year. The company is forecast to post earnings per share of ₹20.80 for next year compared to ₹17.73 last year. Reported Earnings • Aug 18
First quarter 2022 earnings released: EPS ₹5.80 (vs ₹5.36 in 1Q 2021) The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2022 results: Revenue: ₹4.47b (up 45% from 1Q 2021). Net income: ₹978.7m (up 6.7% from 1Q 2021). Profit margin: 22% (down from 30% in 1Q 2021). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • Jun 16
Investor sentiment improved over the past week After last week's 16% share price gain to ₹394, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 63% over the past three years. Reported Earnings • May 28
Full year 2021 earnings released: EPS ₹17.72 (vs ₹13.94 in FY 2020) The company reported a decent full year result with improved earnings and profit margins, although revenues were flat. Full year 2021 results: Revenue: ₹13.3b (flat on FY 2020). Net income: ₹3.01b (up 26% from FY 2020). Profit margin: 23% (up from 18% in FY 2020). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Price Target Changed • Feb 10
Price target raised to ₹470 Up from ₹425, the current price target is an average from 2 analysts. The new target price is 69% above the current share price of ₹278. As of last close, the stock is up 10% over the past year. Reported Earnings • Feb 05
Third quarter 2021 earnings released: EPS ₹4.47 (vs ₹4.31 in 3Q 2020) The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: ₹3.75b (up 17% from 3Q 2020). Net income: ₹752.5m (up 1.5% from 3Q 2020). Profit margin: 20% (down from 23% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Is New 90 Day High Low • Feb 05
New 90-day low: ₹288 The company is down 13% from its price of ₹332 on 06 November 2020. The Indian market is up 23% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₹147 per share. Is New 90 Day High Low • Jan 21
New 90-day low: ₹312 The company is down 10.0% from its price of ₹347 on 23 October 2020. The Indian market is up 24% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₹89.28 per share. Reported Earnings • Nov 10
Second quarter 2021 earnings released: EPS ₹5.15 The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₹3.90b (up 13% from 2Q 2020). Net income: ₹880.8m (up 63% from 2Q 2020). Profit margin: 23% (up from 16% in 2Q 2020). The increase in margin was driven by higher revenue. Analyst Estimate Surprise Post Earnings • Nov 10
Revenue and earnings beat expectations Revenue exceeded analyst estimates by 14%. Earnings per share (EPS) also surpassed analyst estimates by 22%. Over the next year, revenue is forecast to grow 16%, compared to a 12% growth forecast for the Pharmaceuticals industry in India. Is New 90 Day High Low • Oct 08
New 90-day high: ₹367 The company is up 54% from its price of ₹239 on 10 July 2020. The Indian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 18% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₹286 per share.